Spanish distributor Disproquima has acquired Italian outfit RES Pharma srl, which provides ingredients for the cosmetic, pharmaceutical, food and nutraceutical industries.
The Facchini family, the former majority owners of Res Pharma, had already sold the Res Pharma Industriale business unit, which is specialized in the research, innovation and production of personal care ingredients, to Sharon Laboratories in March 2022.
Disproquima said the acquisition of RES Pharma srl strengthened its position in the global market and demonstrates its commitment to providing clients with an ever broader range of innovative, sustainable, and market-trend-focused solutions.
“We are thrilled to announce the acquisition of RES Pharma, a company that shares our commitment to excellence and innovation in the Life Science Industry,” said added Jordi Sánchez.
“This strategic move allows us to enhance our capabilities and further support our clients with a comprehensive suite of products and services”.
RES Pharma, with a history spanning 60 years, said it has been a key player in carefully selecting and providing top-tier ingredients to its clients.
The company’s dedication to offering 360° solutions, encompassing innovation, sustainability, and current market trends, aligns seamlessly with Disproquima’s values and vision for the future.
“This acquisition marks an exciting chapter for RES Pharma,” said president Letizia Facchini.
“Joining forces with Disproquima opens up new opportunities for us to continue delivering exceptional value to our customers. Together, we can leverage our strengths to create a more significant impact on the global life science industry.”